Researchers in Japan are developing world-leading expertise in making and using the alpha particle emitter, astatine-211 (211 At), which has potential for use as a strong radionuclide therapy for ...

Astatine-211 (At-211) is a promising alpha emitting radioisotope for cancer therapy, but its short 7.2-hour half-life means ...

Following a competitive tender process, Arrabawn selected Astatine as its solar partner. The Dublin-based green energy ...

Irish renewables specialist company Astatine has been selected by international energy provider Engie to build three new solar farms in Ireland next year. The new solar farms, located in Galway ...